**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:** CAN/2016-2017/272

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | BDOCIN 150 TABLETS USP | | **REF. NO: NDQD201608064** |
| **DATE RECEIVED:** 04.08.2016 | **LABEL CLAIM:** | Each film coated tablet contains: Capecitabine USP 150 mg. | |
| **BATCH NO.:** TCP2B140415 | **PRESENTATION:** | Pink coloured, circular shaped, biconvex faced tablets, packed in blister strips in a box containing a single strip of 10 tablets. | |
| **MFG. DATE:** Dec. 2015 | **MANUFACTURER:** | BDR Pharmaceuticals Int'l. Pvt. Ltd | |
| **EXP. DATE:**  Nov. 2017 | **ADDRESS:** | R.S No. 578, Near Effluent Channel Road, Vill. Luna, Tal. Padra, Dist. Vadodara - 391440 Gujarat, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | Ripple Pharmaceuticals Ltd., P. O. BOX 10935 - 00100, Nairobi, KENYA. | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

**RESULTS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPENDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | BP 2016 Vol. V App. XII C | NMT 2 tablets deviate by more than 7.5% from mean tablet weight | None deviates | **COMPLIES** |
| **Identification** | HPLC | USP 38 NF 33 Page 2567 | Retention time of the major component peak in the assay sample preparation corresponds to that in the assay standard preparation. | Super-imposable peak at RT 15.5 +/- 10% min present in both the assay sample and standard preparation. | **COMPLIES** |
| **Dissolution** | UV | USP 38 NF 33 Page 2567 | No tablet less than 85% | Average | **COMPLIES** |
| **Dissolution** |  |  |  | 91% Range |  |
| **Dissolution** |  |  |  | 89 - 91% (RSD=0.8%; n=6) |  |
| **Assay** | HPLC | USP 38 NF 33 Page 2567 | 93.0% - 105.0% | 96.0% (RSD=0.7%; n=9) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
| **ANALYST:** | SARAH KARIUKI | .......................................................... | DATE: 09-06-2016 |
| **REVIEWER:** | NICHOLAS MWAURA | .......................................................... | DATE: 10-10-2016 |
| **ANALYST:** | ERNEST MBAE | .......................................................... | DATE: 10-18-2016 |
| **DIRECTOR:** | HEZEKIAH CHEPKWONY | .......................................................... | DATE: 11-18-2016 |